Browsing Tag
Johnson & Johnson
119 posts
Johnson & Johnson posts sustained superiority for IMAAVY in gMG vs rival FcRn blockers in 24-week indirect comparison
New 24-week comparison shows Johnson & Johnson’s IMAAVY outperforms other FcRn blockers in gMG control—see what this means for patients and investors.
How Protagonist Therapeutics is building a multi‑indication macrocyclic peptide portfolio with icotrokinra and beyond
Protagonist Therapeutics is building a multi-indication oral biologics platform with icotrokinra and rusfertide. Learn how its macrocyclic peptides are redefining therapy.
Johnson & Johnson’s DARZALEX FASPRO shows 95% survival at 4 years in multiple myeloma
DARZALEX FASPRO shows 95% four-year PFS and deep MRD responses in NDMM, raising its profile as a foundational frontline therapy. Read the full trial analysis.
Leyden Labs secures €20m from European Investment Bank: Could this reshape Europe’s pandemic response strategy?
Leyden Labs secures €20M EIB funding under HERA Invest to develop intranasal antibody sprays targeting pandemic flu and respiratory threats.
Halozyme Therapeutics stock rises 6.27% after beating Q1 expectations, raising 2025 outlook
Halozyme Therapeutics stock rose as Q1 earnings beat expectations and 2025 guidance improved. See how ENHANZE® drives royalty growth and future prospects.
China just blinked: U.S. drugs spared from tariff hike—Here’s what that means
China exempts select U.S. pharmaceuticals from new 125% tariffs; firms like CSL and Merck assess supply chain resilience.
Johnson & Johnson’s TAR-200 delivers over 80% disease-free survival, offering new hope in BCG-unresponsive high-risk papillary NMIBC
Discover how Johnson & Johnson’s TAR-200 is redefining bladder cancer treatment with over 80% disease-free survival and 94% bladder preservation today!
Why did Corcept, Johnson & Johnson, and Southwest Airlines fall on April 1, 2025?
Corcept, Johnson & Johnson, and Southwest Airlines lead US stock losses as biotech and airline sectors react to trade policy jitters on April 1, 2025.
Johnson & Johnson’s $55bn bet: What it means for healthcare and investors
Johnson & Johnson is investing $55 billion in U.S. manufacturing, R&D, and technology, reinforcing its leadership in pharmaceuticals. Find out more.
Johnson & Johnson’s icotrokinra demonstrates superiority in plaque psoriasis trials, setting stage for market disruption
New clinical trial data from Johnson & Johnson suggests that icotrokinra results could mark a major shift in…